Octreotide Dosage and Administration

Introduction to Octreotide

The initial dose of octreotide for subcutaneous administration is 50-100 mcg two to three times daily, with specific starting doses varying by indication 1

Clinical benefit may be seen with doses as low as 50 mcg, while some patients require up to 1500 mcg/day 1
Patients with VIPomas often respond dramatically to small doses 1

Short-acting formulations may be used for patient stabilization and management of carcinoid crisis 2
Patients may be stabilized with short-acting octreotide for 10-28 days before converting to long-acting somatostatin analogues 1
Dose escalation is often needed over time 1
For VIPomas, titrate dose against vasoactive intestinal peptide levels with normalization of levels as the target 1

For carcinoid crisis prevention during procedures, use short-acting octreotide by intravenous administration (50 mcg/h) 12 hours before, during, and 48 hours after the procedure 1
For chemotherapy-induced diarrhea, starting dose of 100-150 mcg subcutaneous/intravenous three times daily, which can be titrated up to 500 mcg three times daily or 25-50 mcg/h by continuous IV infusion 3

Octreotide is not effective in controlling hypoglycemia in most patients with insulinoma (only effective in SSTR 2-positive cases) 2
Somatostatin receptors are present in 70-95% of NETs but only in about half of insulinomas 1
Side effects include fat malabsorption, gallstones, gallbladder dysfunction, vitamin A and D malabsorption, headaches, diarrhea, dizziness, and hypo/hyperglycemia 1
For optimal imaging with somatostatin receptor scintigraphy, short-acting octreotide should be withdrawn 24-48 hours before imaging 2
In patients with non-functioning NETs, the routine use of somatostatin analogues cannot be recommended until further evidence is available 4